Novel therapeutic approaches to lupus glomerulonephritis: Translating animal models to clinical practice

American Journal of Kidney Diseases

Volumn 57, Issue 3, 2011, Pages 498-507

  Bagavant, Harini ^a   Kalantarinia, Kambiz ^a   Scindia, Yogesh ^a   Deshmukh, Umesh ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

gene therapy; glomerular targeting; glomerulonephritis; immunoliposomes; lupus nephritis; Mesangial cells; mouse models

Indexed keywords

IMMUNOLIPOSOME; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; CASE REPORT; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG DELIVERY SYSTEM; FEMALE; GENE CONTROL; GENETIC SUSCEPTIBILITY; GLOMERULOSCLEROSIS; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOFLUORESCENCE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PROLIFERATIVE GLOMERULONEPHRITIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 79951771261     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2010.10.052     Document Type: Article

References (60)

1. Cameron JS. Systemic lupus erythematosus. In: Neilson EG, Couser WG, eds. Immunologic Renal Diseases. 2nd ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001:1057-1104.
2. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenylate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong Guangzhou Nephrology Study Group. N Engl J Med. 2000;343(16):1156-1162.
3. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350(10):971-980. (Pubitemid 38269274)
4. Grimaldi CM, Hicks R, Diamond B. B Cell selection and susceptibility to autoimmunity. J Immunol. 2005;174(4):1775-1781. (Pubitemid 40223915)
5. Krishnan S, Farber DL, Tsokos GC. T Cell rewiring in differentiation and disease. J Immunol. 2003;171(7):3325-3331. (Pubitemid 37254530)
6. + T cells from lupus-prone Fas-intact MRL mice display TCR-mediated hyperproliferation due to intrinsic threshold defects in activation. J Immunol. 2005;174(8):5100-5109.
7. Cervera R, Khamashta MA, Font J, et al. European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82(5):299 308.
8. Pollack VE, Pirani CL. Renal histologic findings in systemic lupus erythematosus. Mayo Clin Proc. 1969;44(9):630-644.
9. Crispín JC, Liossis SN, Kis-Toth K, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med. 2010;16(2):47-57.
10. Yurasov S, Tiller T, Tsuiji M, et al. Persistent expression of autoantibodies in SLE patients in remission. J Exp Med. 2006;203(10):2255-2261. (Pubitemid 44498360)
11. Chan OT, Hannum LG, HabermanAM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med. 1999;189(10):1639-1648.
12. Eisenberg R, Albert D. B-Cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2006;2(1):20-27. (Pubitemid 43153645)
13. Furie R, Looney RJ, Rovin B, et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (Ln): results from the randomized, double-blind phase III LUNAR Study. (ACR abstract 1149) Arthritis Rheum. 2009;60(suppl 10):271.
14. Harman C. Glomerular disease: lupus nephritis trials end in disappointment. Nat Rev Nephrol. 2009;5(6):303.
15. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222-233.
16. Kawabata D, Venkatesh J, Ramanujam M, Davidson A, Grimaldi CM, Diamond B. Enhanced selection of high affinity DNA-reactive B cells following cyclophosphamide treatment in mice. PLoS One. 2010;5(1):e8418.
17. Ramanujam M, Bethunaickan R, Huang W, Tao H, Madaio MP, Davidson A. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum. 2010;62(5):1457-1468.
18. Dall'Era M, Wofsy D. Systemic lupus erythematosus clinical trials-an interim analysis. Nat Rev Rheumatol. 2009;5(6):348-351.
19. Dall'Era M, Wofsy D. Connective tissue diseases: belimumab for systemic lupus erythematosus: breaking through? Nat Rev Rheumatol. 2010;6(3):124-125.
20. Waters ST, McDuffie M, Bagavant H, et al. Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis. J Exp Med. 2004;199(2):255-264. (Pubitemid 38129705)
21. Kono DH, Theofilopoulos AN. Genetics of SLE in mice. Springer Semin Immunopathol. 2006;28(2):83-96. (Pubitemid 46628478)
22. Waters ST, Fu SM, Gaskin F, et al. NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci. Clin Immunol. 2001;100(3):372-383.
23. Rudofsky UH, Evans BD, Balaban SL, Mottironi VD, Gabrielsen AE. Differences in expression of lupus nephritis in New Zealand mixed H-2z-homozygous inbred strains of mice derived from New Zealand black and New Zealand white mice. Lab Invest. 1993;68(4):419-425.
24. Morel L, Rudofsky UH, Longmate JA, Schiffenbauer J, Wakeland EK. Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity. 1994;1(3):219-229.
25. Vidal S, Kono DH, Theofilopoulous AN. Loci predisposing to autoimmunity in MRL-Fas lpr and C57BL/6-Faslpr mice. J Clin Invest. 1998;101(3):696-702. (Pubitemid 28084255)
26. Birmingham DJ, Rovin BH, Yu CY, Hebert LA. Of mice and men: the relevance of the mouse to the study of human SLE. Immunol Res. 2001;24(2):211-224. (Pubitemid 32897080)
27. Vlahakos DV, Foster MH, Adams S, et al. Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney Int. 1992;41(6):1690-1700.
28. Fu Y, Du Y, Mohan C. Experimental anti-GBM disease as a tool for studying spontaneous lupus nephritis. Clin Immunol. 2007;124(2):109-118. (Pubitemid 47059046)
29. Christensen M, Su AW, Snyder RW, Greco A, Lipschutz JH, Madaio MP. Simvastatin protection against acute immunemediated glomerulonephritis in mice. Kidney Int. 2006;69(3):457-463. (Pubitemid 43164436)
30. Lema P, Maier H, Nieto E, et al. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol. 2001;12(7):1369-1382. (Pubitemid 32666320)
31. Alexopoulos E, Seron D, Hartley RB, Cameron JS. Lupus nephritis: correlation of interstitial cells with glomerular function. Kidney Int. 1990;37(1):100-109. (Pubitemid 20023773)
32. Diaz Gallo C, Jevnikar AM, Brennan DC, Florquin S, Pacheco-Silva A, Kelley VR. Autoreactive kidney-infiltrating T-cell clones in murine lupus nephritis. Kidney Int. 1992;42(4):851-859.
33. Bagavant H, Deshmukh US, Wang H, Ly T, Fu SM. Role for nephritogenic T cells in lupus glomerulonephritis: progression to renal failure is accompanied by T cell activation and expansion in regional lymph nodes. J Immunol. 2006;177(11):8258-8265. (Pubitemid 44846348)
34. + T cells is required to suppress autoimmunity. J Immunol. 1992;149(9):3083-3088.
35. Wenderfer SE, Stepkowski SM, Braun MC. Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist. Kidney Int. 2008;4(10):1319-1326.
36. Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol. 2001;166(5):2913-2916. (Pubitemid 33117284)
37. Schiffer L, Sinha J,Wang X, et al. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J Immunol. 2003;171(1):489-497. (Pubitemid 36745324)
38. + T cells from lupus-prone mice to suppress lupus glomerulonephritis and sialoadenitis. J Immunol. 2005;175(2):944-950.
39. Smith J, Lai PC, Behmoaras J, et al. Genes expressed by both mesangial cells and bone marrow-derived cells underlie genetic susceptibility to crescentic glomerulonephritis in the rat. J Am Soc Nephrol. 2007;18(6):1816- 1823. (Pubitemid 46870318)
40. Xie C, Sharma R, Wang H, Zhou XJ, Mohan C. Strain distribution pattern of susceptibility to immune-mediated nephritis. J Immunol. 2004;172(8):5047-5055. (Pubitemid 38456432)
41. Liu K, Li QZ, Delgado-Vega AM, et al. Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans. J Clin Invest. 2009;119(4):911-923.
42. Morimoto K, Kondo M, Kawahara K, et al. Advances in targeting drug delivery to glomerular mesangial cells by long circulating cationic liposomes for the treatment of glomerulonephritis. Pharm Res. 2007;24(5):946-954. (Pubitemid 46675395)
43. Bangham A. Surrogate cells or Trojan horses: the discovery of liposomes. Bioessays. 1995;17(21):1081-1088.
44. Madsen K, Tisher CC. Anatomy of the kidney. Elements of normal renal structure and function. In: Brenner BM, ed. Brenner & Rector's The Kidney. 7th ed. Philadelphia, PA: W.B. Saunders Co; 2004:3-72.
45. Carl MY, Akagi S, Weidner S, Isaka Y, Imai E, Rupprecht HD. Specific inhibition of Egr-1 prevents mesangial cell hypercellularity in experimental nephritis. Kidney Int. 2003;63(4):1302-1312. (Pubitemid 36349996)
46. Tomita N, Kim JY, Gibbons GH, et al. Gene therapy with an E2F transcription factor decoy inhibits cell cycle progression in rat anti-Thy 1 glomerulonephritis. Int J Mol Med. 2004;13(5):629-636.
47. Ahn JD, Morishita R, Kaneda Y, et al. Transcription factor decoy for AP-1 reduces mesangial cell proliferation and extracellular matrix production in vitro and in vivo. Gene Ther. 2004;11(11):916-923. (Pubitemid 38786606)
48. Shimizu H, Hori Y, Kaname S, et al. siRNA-based therapy ameliorates glomerulonephritis. J Am Soc Nephrol. 2004;21(4):622-633.
49. Kaneda Y, Saeki Y, Morishita R. Gene therapy using HVJ liposomes: the best of both worlds. Mol Med Today. 1999;5(7):298-303. (Pubitemid 29302677)
50. Asgeirsdóttir SA, Zwiers PJ, Morselt HW, et al. Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded Ab Esel liposomes. Am J Physiol Renal Physiol. 2008;294(3):554-561.
51. Jeong HS, Park KK, Kim SP, Choi IJ, Lee IK, Kim HC. Effect of antisense TGF-beta1 oligodeoxynucleotides in streptozotocin induced diabetic rat kidney. J Korean Med Sci. 2004;19(3):374-383. (Pubitemid 38859827)
52. Kang JH, Chae YM, Park KK, Kim CH, Lee IS, Chang YC. Suppression of mesangial cell proliferation and extracellular matrix production in streptozotocin-induced diabetic rats by Sp1 decoy oligodeoxynucleotide in vitro and in vivo. J Cell Biochem. 2008;103(2):663-674.
53. Tomita N, Higaki J, Morishita R, et al. Direct in vivo gene introduction into rat kidney. Biochem Biophys Res Commun. 1992;186(1):129-134.
54. Tomita N, Morishita R, Yamamoto K, et al. Targeted gene therapy for rat glomerulonephritis using HVJ-immunoliposomes. J Gene Med. 2002;4(5):527-535. (Pubitemid 40268379)
55. Scindia YM, Deshmukh US, Bagavant H. Mesangial pathology in glomerular disease: targets for therapeutic intervention. Adv Drug Deliv Rev. 2010;62(14):1337-1343.
56. Tuffin G, Waelti E, Huwyler J, Hammer C, Marti HP. Immunoliposome targeting to mesangial cells: a promising strategy for specific drug delivery to the kidney. J Am Soc Nephrol. 2005;16(11):3295-3305. (Pubitemid 46179334)
57. Scindia Y, Deshmukh U, Thimmalapura PR, Bagavant H. Anti-α8 integrin immunoliposomes in glomeruli of lupus-susceptible mice: a novel system for delivery of therapeutic agents to the renal glomerulus in systemic lupus erythematosus. Arthritis Rheum. 2008;58(12):3884-3891.
58. Schnapp LM, Breuss JM, Ramos DM, Sheppard D, Pytela R. Sequence and tissue distribution of the human integrin alpha subunit: beta1-associated alpha subunit expressed in smooth muscle cells. J Cell Sci. 1995;108(2):537-544.
59. Bagavant H, Scindia Y, Nandula S, Deshmukh U. Role of T cell mediated inflammation in lupus-like glomerulonephritis (GN) [AAI abstract 93.40]. J Immunol. 2010;184:93.40.
60. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res. 2002;8(4):1172-1181. (Pubitemid 35177372)